Edgewise Therapeutics Inc (EWTX) Return on Investment ROI from the third quarter of 2026 to third quarter of 2025 and for the year 2026, average high and low, overall ranking from Sep 30 2026 to Sep 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Edgewise Therapeutics inc   (NASDAQ: EWTX)


Edgewise Therapeutics Inc's ROI from its third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Edgewise Therapeutics Inc's ROI in the third quarter of 2026?
Edgewise Therapeutics inc achieved a return on average invested assets (ROI) of 129.94 % in its third quarter of 2026, this is above EWTX's average return on investment of -25.68%.
Edgewise Therapeutics Inc invested over the 12 months ending in its third quarter of 2026 $777 million

ROI has improved compared to -38.79% in the second quarter of 2026, due to net income growth.

Within the Healthcare sector 412 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the second quarter of 2026 from 3439 to 3516.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Investment Change TTM 51.56 % 2.66 % 14.32 % 5.17 % 9.69 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 1,636 451 496 525 562
Return On Investment (TTM) 129.94 % -38.79 % -32.36 % -31.77 % -30.67 %
EWTX's Overall Ranking # 3516 # 3439 # 2034 # 3224 #
Seq. Investment Change TTM 52.82 % -6.52 % 2.97 % 3.04 % 3.51 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions 1,010 -197 -176 -168 -157

EWTX Company Profile >> Back to EWTX Roi Comparisons >> See Annual EWTX Return On Investment



Return On Investment EWTX's Ranking
Within: No.
Industry # 164
Sector # 413
Overall # 3516

Return On Investment Statistics
High Average Low
-3.34 %
-25.68 %
-38.79 %
(Mar 31 2021)   (Jun 30 2026)







Financial Statements
Edgewise Therapeutics Inc's III. Quarter Investments $ 1,636 Millions EWTX's Balance sheet
Edgewise Therapeutics Inc's III. Quarter Income $ 1,166 Millions Quarterly EWTX's Income Statement
EWTX's Income by Division See EWTX's Income by Division


EWTX Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 525 463 323 351 275
Y / Y Investment Growth 13.45 % 43.21 % -7.77 % 27.59 % -
Net Income in Millions -168 -134 -100 -68 -43
Y / Y Net Income Growth - - - - -
Annual Return On Investment -31.95 % -28.9 % -30.98 % -19.3 % -15.58 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
EWTX's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for EWTX's Competitors
Subscribers only: Roi for Edgewise Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for EWTX's Customers

Other Ratios
EWTX's Roa EWTX's Inventory Turnover Ratio EWTX's Growth Rates EWTX's Dividend Statistics
EWTX's Profitability Ratios EWTX's Asset Turnover Ratio EWTX's Dividend Growth
EWTX's Roe EWTX's Valuation Ratios EWTX's Financial Strength Ratios EWTX's Dividend Payout Ratio



Companies with similar Return On Investment at Sep 30 2026, within Healthcare Sector ROI
Vor Biopharma Inc   293.36 %
Indivior Pharmaceuticals Inc   108.22 %
Exelixis Inc   75.01 %
Ironwood Pharmaceuticals inc   68.68 %
Rigel Pharmaceuticals Inc  68.50 %
Alnylam Pharmaceuticals Inc   63.14 %
Idexx Laboratories Inc  52.51 %
Aurinia Pharmaceuticals Inc   45.04 %
Nurix Therapeutics Inc   44.12 %
Medpace Holdings Inc   41.14 %
Rallybio Corporation  36.04 %
Eli Lilly And Company  32.00 %
Caredx Inc   30.65 %
Zevra Therapeutics Inc   29.88 %
Acadia Pharmaceuticals Inc   26.89 %

Date modified: 2026-11-05T10:30:28+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.